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Abstract
Purpose The production of epithelial neutrophil activat-
ing peptide-78 (NA-78) and the interleukins IL-8 and IL-6
by endometrial stromal cells is stimulated by pro-inflam-
matory interleukin-1 (IL-1) and tumour necrosis factor-a
(TNF-a). IL-8 is suggested to play a role in the patho-
genesis of endometriosis, and in these women the perito-
neal fluid concentrations of ENA-78 and IL-8 are
increased. TNF-a has been tested together with interferon-c
because of their cooperative stimulation of IL-6. The
release of IL-8, however, is inhibited with increasing
interferon levels. The aim of the study was the analysis of
the production of ENA-78, IL-6 and IL-8 by cultured
human endometrial stromal cells in the presence of varying
concentrations of IL-1b, TNF-a, and interferon-c.
Methods Eutopic endometrial tissue was obtained from
seven cycling, endometriosis-free women undergoing lap-
aroscopy for reasons of infertility or pain. The release of
ENA-78, IL-8 and IL-6 by the isolated and monolayer
cultured stromal cell fraction in the presence of IL-1b (0.08
to 50 ng/mL), TNF-a, and interferon-c (both 20 to 500 ng/
mL) was determined.
Results IL-1b stimulated the production of IL-8, IL-6,
and ENA-78 dose dependently from 0.08 to 2.0 ng/mL
(ENA-78) or to 10 ng/mL (IL-8, IL-6); at 50 ng/mL a
decrease in release was observed for IL-8 and IL-6. TNF-a
stimulation yielded a plateau between 20 and 100 ng/mL.
Interferon-c stimulated IL-6 and inhibited IL-8 production
above 20 ng/mL. ENA-78 release was largely unaffected
by interferon-c.
Conclusions IL-1b and TNF-a stimulate stromal cytokine
production cumulatively with different dose–response
curves. The presence of interferon-c has opposite effects on
IL-8 and IL-6. TNF-a and interferon-c should be investi-
gated separately in future in vitro studies with endometrial
cells and explants.
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Introduction
Epithelial neutrophil activating peptide-78 (ENA-78) and
interleukin-8 (IL-8) are structurally and functionally rela-
ted chemokines of the C-X-C type and for which angio-
genic properties have been demonstrated [1]. The
production of ENA-78 is stimulated by the addition of the
pro-inflammatory cytokine IL-1 not only in monocytes and
neutrophils [2], but also in stromal cells isolated from
human endometrium [3]. Tumour necrosis factor-a (TNF-a),
another proinflammatory cytokine, also stimulates ENA-78
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in endometrial stromal cells [3] and TNF-a neutralising
antibodies inhibit the expression of ENA-78 in eosinophils
[4]. These results suggested an upregulation of ENA-78
and IL-8 in the inflammatory state, an observation which is
clinically relevant in endometriosis. This pathology is
characterised by endometrial tissue present outside the
uterus and responding to hormonal and inflammatory
stimulation, and which often results in dysmenorrhoea,
debilitating pain and thus in a significant reduction in the
quality of life [5]. Endometriosis is a chronic, oestrogen-
dependent disease affecting approximately 10% of women
during reproductive age. IL-6 and IL-8 have been sug-
gested to play a role in the pathogenesis of the disease
[6–8], and we as well as other investigators have found
increased concentrations of ENA-78 [9, 10], IL-6 [11–13],
and IL-8 [7, 14] in the peritoneal fluid of women with
endometriosis.
Monolayer cultured eutopic endometrial stromal cells
increased their output of IL-8 and ENA-78 by up to 500-
fold in the presence of added IL-1b [3], and we were
able to confirm this finding not only for stromal cells but
also for the epithelial compartment—although to a less
pronounced extent [15]. Such stimulation was similarly
confirmed in the presence of TNF-a either added alone
[16] or in combination with interferon-c [15]. The two
molecules were used together because of their coopera-
tive stimulation of monocyte chemoattractant protein-1,
macrophage colony stimulating factor, RANTES and
IL-6 production in monocytes. In endometrial stromal
cells, interferon-c administered alone has similarly been
shown to stimulate the production of IL-6 and several
other cytokines in a dose-dependent manner, while the
release of IL-8 was progressively inhibited by increasing
interferon levels [17]. The role of interferon-c (IFN-c) on
stimulated and non-stimulated endometrial stromal cells
therefore remains unclear. An anti-proliferative action of
this cytokine on epithelial cells has, however, been
shown [18]. In the endometrium, IFN-c is produced by
natural killer cells [19]; it plays a role in angiogenesis
and endometrial tissue modelling [19], and favours the
establishment and maintenance of a successful pregnancy
[17].
The aim of this study was to find out whether it was
indeed necessary to investigate the effects of TNF-a and
interferon-c on endometrial stromal cells separately, and to
compare them with IL-1b mediated effects which have
been shown to be more pronounced [3, 15]. We have thus
decided to construct dose–response curves as a function of
different concentrations of IL-1b, TNF-a and interferon-c,
administered either individually or in combination, to
cultured stromal cells. We were able to show different
stimulation or inhibition response patterns for IL-6, IL-8,
and ENA-78.
Materials and methods
Endometrial tissue was biopsied with a soft suction curette
(Pipelle-de-Cornier, Laboratoire CCD, Paris, France) in
the proliferative phase from pre-menopausal women
undergoing laparoscopic investigations in our clinic. The
study protocol was approved by the Ethical Committee of
the University of Berne. Due to the large number of
required cells, replicate cultures to set up, and measure-
ments planned in this preliminary in vitro experiment,
biopsied tissue samples from three of the seven patients
were pooled prior to purification. For the same reason
(amount of biological material required), it was not
attempted to perform this experiment with purified epi-
thelial endometrial cells.
In order to provide a homogeneous group of replicate
tissue sample the absence of endometriosis was ascertained
histologically and no reported gynaecological pathology,
except the presence of abdominal pain, was allowed to be
present. Also, as a large amount of biological material was
required, the study was restricted to stromal cells which are
easy to grow and to passage in monolayer cultures. As a
consequence, a total of four experiments of isolation and
cultures were performed (see next paragraph). Stromal
cells were prepared according to Ryan et al. [20] in a
protocol described recently [15] based on collagenase
digestion and stepwise sieving down to 40 lm. Cultures
were prepared by the dispersion of the cells in complete
IMDM medium (Iscove’s modified Dulbecco’s medium)
containing Hepes (25 mM), stabilised glutamine (Gluta-
max), foetal bovine serum (10% v/v), penicillin, strepto-
mycin, and fungizone (all from Gibco-Invitrogen, Paisley,
Scotland) in 75 cm2 culture flasks, and the medium
(12.5 mL) was changed after 30 min of incubation to
remove dead material, residual red blood and other non-
attaching (including deteriorated stromal) cells. The
attached endometrial stromal cells were grown to conflu-
ence at 37C under 5% CO2 in air in complete IMDM
medium and passaged twice before starting the cytokine
stimulation experiment. Then the cells were harvested by
trypsinisation, and distributed into four 48-well (Nunclon
SurfaceTM, Roskilde, Denmark) culture plates (20,000 cells
in 1.0 mL medium per well) in complete IMDM medium
until they reached 80% of confluence.
The biopsied material obtained from the first three
patients was pooled prior to the isolation of endometrial
stromal cells, and duplicate culture wells were set up with
this population. Preparations from the next four patients
were set up individually but singly, which thus resulted in
six culture wells per cytokine concentration combination.
The following cytokines, all purchased from R&D
Systems, Abingdon, Oxford, England, were introduced to
the following final concentrations: recombinant human
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IL-1b, Cat. No. 201-LB, 0, 0.08, 0.4, 2.0, 10, 50 ng/mL;
recombinant human INF-a, Cat. No. 210-TA, 0, 20, 100,
500 ng/mL; recombinant human IFN-c, Cat. No. 285-IF, 0,
20, 100, 500 ng/mL. Introducing all possible combinations
of these concentrations, a total of 576 culture wells had
been set up in this study. After 24 h of culture the super-
natants were removed, centrifuged, and individually stored
at -30C until IL-6, IL-8 and ENA-78 protein concentra-
tions were determined batchwise in these media.
ENA-78 and IL-8 concentrations in the conditioned
media were determined by microplate ELISA as reported
previously [15]. The assay for IL-6 was developed as it had
been done for IL-8 using ‘‘matched pair’’ antibodies [21];
capture and biotinylated detection antibody concentrations
for IL-6 were 2.0 and 0.25 lg/mL. All reagents (antibodies
and recombinant standards) were obtained from R&D
Systems, and the range of the standard curve for IL-6 was
12.5–800 pg/mL in serial 1:2 dilution steps. Culture
supernatants were diluted between 1:2 and 1:500 in Blotto
(Pierce, USA; Socochim, Lausanne, Switzerland). All other
assay parameters and conditions were unchanged from the
protocol published for IL-8 [21]. Cytotoxicity of the culture
conditions after 24 h was assessed by the determination of
lactate dehydrogenase released (LDH) into the medium
through loss of the membrane barrier function, using the
reagent kit obtained from Roche (Rotkreuz, Switzerland,
Cat. No. 47449 26001) on microplates. Culture media were
diluted 1:2 in serum-free IMDM prior to assay. The pro-
tocol supplied by the manufacturer was followed with a
30 min incubation at 30C, and the signal was normalised
against blank medium containing 5% (v/v) foetal bovine
serum from the same batch as the one used in culture. This
had to be done due to the considerable but varying amounts
of lactate dehydrogenase present in FCS.
Cyto- and chemokine (ENA-78, IL-6, IL-8) production
data were plotted firstly as raw concentrations (in ng/mL or
pg/mL), as measured in the cultures run with tissue pooled
from three patients, in three-dimensional graphs as a
function of the concentrations of two of the three stimu-
lators/inhibitors (IL-1b, TNF-a, IFN-c) at a time. 3D
graphs were created using Microsoft Excel. In this series
each data column corresponded to a duplicate ELISA
measurement from duplicate culture wells. For the com-
bined analysis of the four separate cultures from the seven
women, the readings were normalised with respect to the
lowest IL-1b concentration added (0.08 ng/mL), and
standard deviations were calculated with Prism software
(Graphpad, San Diego, CA, USA). The cultures run in the
total absence of IL-1b and TNF-a could not be used for
normalisation since ENA-78 and IL-8 was not detected
under these conditions (division by zero). For this reason,
no cross-sectional or grouped statistical analysis could be
performed and it was decided to present the results in three-
dimensional dose–response bar graphs as a function of the
increasing concentrations of the stimulators/inhibitors
added.
Results
The production of IL-8, IL-6, and ENA-78 by cultured
endometrial stromal cells was stimulated by the presence of
IL-1b at 0.08 ng/mL and higher, and by TNF-a at 20 ng/
mL or higher. This effect was dose dependent and cumu-
lative between IL-1b and TNF-a for all three endpoint
markers (Fig. 1), and cumulative between IL-1b and IFN-c
for IL-6 only (at least up to 100 ng/mL IFN-c, Fig. 2b). In
Figs 1 and 2, each data column represents the mean of
either four (IL-8, IL-6) or three (ENA-78) single cultures
with cells from different patients. A non-linear, ‘‘hook’’
pattern was observed for IL-8 release, with considerably
lower output of this chemokine in the presence of IL-1b at
50 when compared to 10 ng/mL and when TNF-a was
present (Fig. 1a). This pattern was also seen for IL-6,
though to a less pronounced extent (Fig. 1b). ENA-78
production, on the other hand, continued to rise with
increasing IL-1b present in the medium, though we did not
observe a difference in ENA-78 output between 2.0 and
10 ng/mL IL-1b (Fig. 1c) in normalised means over four
culture experiments involving tissue from seven women.
On the other hand, this ‘‘hook’’ pattern (lower production
in presence of 50 when compared to 10 ng/mL of IL-1b)
was observed for all three endpoint markers (IL-8, IL-6 and
ENA-78) with increasing levels of interferon-c in the
absence of TNF-a (Fig. 2). When added to an in vitro
concentration of 20 ng/mL or higher in the absence of IL-
1b, IFN-c inhibited the production of IL-8 (Fig. 3a) but
stimulated the output of IL-6 and ENA-78 into the medium
(Fig. 3b,c).
The cytotoxicity (LDH activity released into the med-
ium) determined in the supernatants after culture did not
vary between conditions as a function of the concentration
(from absent to very high) of any of the cytokines (IL-1b,
TNF-a, or IFN-c) added to the medium (data not shown).
Serum-free, blank media supplemented with cytokines at
the highest concentration yielded an LDH reading below
the detection limit of the assay.
Discussion
The presence of IL-8, IL-6, and ENA-78 in the human
endometrium has been demonstrated immunohistochemi-
cally [3, 22, 23]; but while the two interleukins were
predominantly (but not exclusively) located in the glan-
dular epithelium [22, 23], ENA-78 was found mainly in
Arch Gynecol Obstet (2011) 283:1291–1296 1293
123
the stroma [3]. Nevertheless, only low levels of ENA-78
have been detected in the supernatant of stromal cells
cultured in the absence of stimulation by cytokines or
Fig. 1 Release of IL-8 (a), IL-6 (b), and ENA-78 (c), into the
medium by endometrial stromal cells cultured for 24 h in the
presence of IL-1b (0–50 ng/mL in fivefold dilution steps) and
TNF-a (0, 20, 100, 500 ng/mL). No interferon was present in these
cultures. Values were obtained from one duplicate well culture
with cells obtained after extraction of pooled endometrial tissue
from three patients plus four single well cultures with material
extracted from individually extracted biopsies obtained in four
individual women. Normalisation in each graph was set at 1.00 for
an IL-1b level of 0.08 ng/mL and absence of added TNF-a (for
explanation see ‘‘Materials and methods’’); this reference point is
marked (R) in the graph. Standard deviations ranged between
CV = 16.5 and 80%; they are not shown here for the sake of not
overloading the figures
Fig. 2 Release of IL-8 (a), IL-6 (b), and ENA-78 (c) into the medium
by endometrial stromal cells cultured for 24 h in the presence of
IL-1b (0–50 ng/mL in five-fold dilution steps) and interferon-c (0, 20,
100, 500 ng/mL). No TNF-a was present in these cultures. Values
were obtained from one duplicate well culture with cells obtained
after extraction of pooled endometrial tissue from three patients plus
four single well cultures with material extracted from individually
extracted biopsies obtained in four individual women. Normalisation
in each graph was set at 1.00 for an IL-1b level of 0.08 ng/mL and
absence of added IFN-c (for explanation see Materials and methods);
this reference point is marked (R) in the graph
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lipopolysaccharide [3], and this pattern was the same as
the one reported for IL-6 and IL-8 whose production was
strongly stimulated by the presence of IL-1b or TNF-a in
endometrial explant cultures [24], stromal monolayers
[25, 26] and in a human stromal sarcoma cell line [27].
We have confirmed that cultured endometrial stromal, in
contrast to epithelial, cells indeed only produced very
small amounts of ENA-78 and IL-8 in the absence of in
vitro stimulation, but that the addition of IL-1b or TNF-a
with interferon (IFN-c) increased this output to up to 500-
fold the nonstimulated level [15]. TNF-a and interferon
had been added in combination because of their co-
operative action on several chemo- and cytokines,
including IL-6. Such a cumulative effect, however, does
not seem to occur in the case of IL-8 for which an
inhibitory action of IFN-c had been demonstrated [17].
For ENA-78, no information on possible stimulatory or
inhibitory action of IFN-c is available in the literature.
We have therefore decided to investigate the dose-
dependent effects of IL-1b, TNF-a and IFN-c separated
from each other as well as in combination.
Our results largely confirm the early findings on the
opposite and specific effects of IFN-c on the production
of IL-6 and IL-8 [17] for the endometrium, which is
contrary to the observed stimulation of IL-8 in kerati-
nocytes [28]. On the other hand, we are reporting for the
first time that the production of ENA-78 in the endo-
metrium was not strongly influenced by IFN-c, except
maybe in the presence of very high levels of IL-1b
(50 ng/mL, Fig. 2c). IFN-c is an immunomodulator and a
multifunctional cytokine produced by uterine natural
killer, decidual inflammatory cells and later by the syn-
cytiotrophoblast, and is essential for fertility and preg-
nancy maintenance [19]. Our results presented here
indicate that the effect of IFN-c on the recruitment of T
cells and neutrophils, pertaining to the protective role of
this cytokine, would not be mediated by ENA-78, but
that these two immunomodulators play their role sepa-
rately and independently.
Besides the above observation, ENA-78 showed a trend
towards a stimulation of its release by IFN-c in the absence
of IL-1b (Fig. 3c). In cultures obtained from stromal cells
from three out of six women we have, however, observed
and a slight inhibition when IL-1b was present (not
shown). Further studies with a larger number of replicate
cultures and in the presence of very low IL-1b concentra-
tions are required to determine whether this cytokine would
modulate the action of IFN-c in a negative feedback loop.
Progesterone has also been demonstrated to stimulate the
production of ENA-78 [3, 29]; but again we believe that
this pathway did not play a role in our study since only
biopsies taken in the proliferative phase of the menstrual
cycle were used in culture. It may, however, be interesting
to investigate the action of the mentioned cytokines on
ENA-78 production in the presence and absence of the
steroid hormone.
Fig. 3 Release of IL-8 (a), IL-6 (b), and ENA-78 (c) into the medium
by endometrial stromal cells cultured for 24 h in the presence of
interferon-c and TNF-a (both at 0, 20, 100, 500 ng/mL and in all
combinations). No IL-1b was present in these cultures, and for this
reason the data are not normalised (for explanation see Materials and
methods) and shown for the (duplicate well) culture experiment run
with tissue extracted after pooling the biopsied material from three
patients
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In conclusion, our study illustrates that, in spite of
cumulative effects, the actions of cytokines such as IL-1b,
TNF-a, and IFN-c on the production and release of
immunomodulatory and angiogenic markers in the endo-
metrium follow separate patterns and may show non-linear,
complex dose–response curves. It is therefore necessary to
investigate the in vitro effects of bioactive substances on
endometrial tissue in both separated and combined proto-
cols. Moreover, these protocols will have to be tested on
ectopic endometrium obtained from endometriosis patients.
This is particularly relevant in the context of developing
new, cyto- or chemokine targeted treatment approaches for
this disease which is affecting a large number of women
and to which increased research efforts will have to be
made in the future.
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